06 Jan 2015
Submissions to PBAC on drugs for metastatic breast cancer
BCNA developed and lodged submissions with the Pharmaceutical Benefits Advisory Committee (PBAC) relating to three breast cancer drugs being considered for listing under the Pharmaceutical Benefits Scheme (PBS) at the PBAC's March 2013.
All three drugs are used in the treatment of metastatic breast cancer:
- eribulin mesylate (Halaven®) – a new chemotherapy drug for women whose cancer has progressed on other chemotherapy drugs
- everolimus (Afinitor®) – a new drug for hormone-positive metastatic breast cancer, where the cancer has progressed on hormone therapy
- vinorelbine (Navelbine®) capsules – an oral form of the chemotherapy drug vinorelbine (already listed on the PBS for IV infusion)
We expect the outcomes of the PBAC meeting to be available in late April or May 2013, and we will let women know of the outcomes through our website.
We thank members of BCNA’s Strategic Advisory Group and the Medical Oncology Group of Australia for their assistance in reviewing these submissions.
The full submissions are available to download below.
PBAC meeting outcomes
The outcomes of the PBAC meeting were released on 26 April 2013.
The application for oral vinorelbine (capsules) was successful.
However the applications for everolimus and eribulin mesylate were unsuccessful. The pharmaceutical companies which developed these drugs have advised they will continue to work with the PBAC with the aim of having the drugs approved and listed on the PBS.